Clinical trial / 2015
Macular carotenoid supplementation improved macular pigment and vision but not cognition in Alzheimer's disease.
Thirty-one patients with Alzheimer's disease and 31 age-similar controls received a carotenoid formulation (10 mg meso-zeaxanthin, 10 mg lutein, 2 mg zeaxanthin) or sunflower oil placebo for 6 months. Active supplementation significantly raised serum carotenoid concentrations and macular pigment (p < 0.001 for all) and improved contrast sensitivity (p = 0.039). Cognitive function outcomes showed no significant changes in any measured variable (p > 0.05 for all).
- Study type
- Randomized controlled trial
- Who was studied
- 31 patients with Alzheimer's disease and 31 controls
- What was measured
- Macular pigment, visual function, and cognitive function
THE PAPER
The impact of supplemental macular carotenoids in Alzheimer's disease: a randomized clinical trial.
Nolan JM, Loskutova E, Howard A, Mulcahy R, Moran R, Stack J, Bolger M, Coen RF, Dennison J, Akuffo KO, Owens N, Power R, Thurnham D, Beatty S. J Alzheimers Dis, 2015.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.